22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
Seyfarth Synopsis: On June 11, 2019, New Jersey Governor Phil Murphy signed a law requiring covered ...
Read More >
In a recent published decision, the California Court of Appeal had the opportunity to address this i...
Read More >
Congress recently passed significant legislation affecting employer-sponsored employee benefit plans...
Read More >
In a flurry of decisions issued this month, the Republican majority on the National Labor Relations ...
Read More >
As we are all too aware, on March 10, 2020, Governor Ned Lamont issued declarations of public health...
Read More >
The City of Philadelphia’s effort to ban employers from asking about the wage history of job applic...
Read More >